Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Davide Giuseppe Ribaldone, L Parisio, Angela Variola, Fabrizio Bossa, Fabiana Castiglione, Manuela Marzo, Nicole Piazza, Annalisa Aratari, Edoardo Savarino, Giorgia Bodini, Mauro Mastronardi, Federica Micheli, S. Mazzuoli, M. Ascolani, Chiara Viganò, Maria Cappello, Cristina Bezzio, Rachele Ciccocioppo, Giulia Scardino, Ennio Sarli, Daniela Pugliese, Franco Scaldaferri, Daniele Napolitano, Alessia Todeschini, Andrea Geccherle, N Colaci, María Guerra, Monica Annese, Anna Testa, Anna Caiazzo, Francesco Conforti, Stefano Festa, Greta Lorenzon, Antonella Marra, Ambra Magiotta, Flavia Baccini, Arnaldo Amato, Anxhela Poshnjari, Marta Vernero, Flavio Caprioli, Gian Paolo Caviglia
Topics & Concepts
VedolizumabMedicineUlcerative colitisGastroenterologyInternal medicineDermatologyDiseaseInflammatory Bowel DiseaseBiosimilars and Bioanalytical MethodsMicroscopic Colitis